Cargando…
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted and immunotherapies. Among the different PDAC subtypes, basal-like mesenchymal PDAC, which is driven by allelic imbalance, increased gene-dosage and subsequent high expression levels of oncogeni...
Autores principales: | Falcomatà, Chiara, Bärthel, Stefanie, Widholz, Sebastian A., Schneeweis, Christian, Montero, Juan José, Toska, Albulena, Mir, Jonas, Kaltenbacher, Thorsten, Heetmeyer, Jeannine, Swietlik, Jonathan J, Cheng, Jing-Yuan, Teodorescu, Bianca, Reichert, Oliver, Schmitt, Constantin, Grabichler, Kathrin, Coluccio, Andrea, Boniolo, Fabio, Veltkamp, Christian, Zukowska, Magdalena, Vargas, Angelica Arenas, Paik, Woo Hyun, Jesinghaus, Moritz, Steiger, Katja, Maresch, Roman, Öllinger, Rupert, Ammon, Tim, Baranov, Olga, Robles, Maria S., Rechenberger, Julia, Kuster, Bernhard, Meissner, Felix, Reichert, Maximilian, Flossdorf, Michael, Rad, Roland, Schmidt-Supprian, Marc, Schneider, Günter, Saur, Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612546/ https://www.ncbi.nlm.nih.gov/pubmed/35122074 http://dx.doi.org/10.1038/s43018-021-00326-1 |
Ejemplares similares
-
Genetic Screens Identify a Context-Specific PI3K/p27(Kip1) Node Driving Extrahepatic Biliary Cancer
por: Falcomatà, Chiara, et al.
Publicado: (2021) -
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Falcomatà, Chiara, et al.
Publicado: (2023) -
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
por: Schneeweis, Christian, et al.
Publicado: (2022) -
Non-canonical functions of SNAIL drive context-specific cancer progression
por: Paul, Mariel C., et al.
Publicado: (2023) -
Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)